Former SmokerNCT07134426
Vaped Phenanthrene
A study testing D10-phenanthrene in people with Former Smoker and Non-Smoker, run by University of Minnesota at 1 site in United States.
Trial summary
Some people who used to smoke cigarettes continue to be at higher risk of developing lung cancer, even years after quitting. This study will look to see if a specific chemical, phenanthrene, is broken down in the lungs of former smokers through more harmful pathways than never-smokers. Read more about this study
- Who is it for?
- Ages 21 years and olderHealthy volunteers can take part
- Conditions the study is for
- Former Smoker, Non-Smoker
- What is being tested?
- D10-phenanthrene
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Sep 2026to 30 Jun 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- > 21 years of age
- In good physical \& mental health
- In stable physical \& mental health
- Have tried vaping
- Former daily cigarette smokers who quit 1-20 year ago
- Non-smokers who have not used tobacco or nicotine products
Who cannot join
- Has any respiratory disease (ex - asthma, COPD, etc...)
- Has/had high blood pressure
- Has/had liver disease
- Has/had cancer
- Has experience negative effects when vaped previously
- Pregnant or nursing
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
University of Minnesota
Minneapolis, Minnesota, 55455
Aleksandra Alcheva, 612-422-8902, alche003@umn.edu
About this study
Official title: Investigating Vaped Phenanthrene Biomarkers in Former Smokers
Some people who used to smoke cigarettes continue to be at higher risk of developing lung cancer, even years after quitting. This study will look to see if a specific chemical, phenanthrene, is broken down in the lungs of former smokers through more harmful pathways than never-smokers. If former smokers break down chemicals that enter their lungs through more harmful pathways this might be putting them at higher risk for developing lung cancer even though they quit smoking. This information may help find better ways to prevent or treat cancer in the future.
This study is under an IND, but the drug is not being studied; instead, it is being used as a marker for drug metabolism.
- Conditions
- Former Smoker, Non-Smoker
- Being tested
- D10-phenanthrene
- Keywords
- Smoking, Tobacco, Vaping, Former Smoker, Non-Smoker
- Medical subject headings
- Smoking Cessation, Smoking, Vaping
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
D10-phenanthreneOther
All study participants (Former Daily Smokers and Non-smokers) will be asked to vape D10-phenanthrene to see how their lungs breakdown a class of cancer-causing chemicals known as polycyclic aromatic hydrocarbons [PAHs].
| Study group | Role | What they receive |
|---|---|---|
| D10-phenanthrene | Other | All study participants (Former Daily Smokers and Non-smokers) will be asked to vape D10-phenanthrene to see how their lungs breakdown a class of cancer-causing chemicals known as polycyclic aromatic hydrocarbons [PAHs]. Receives: Other: D10-phenanthrene |
What is being measured
The primary outcome is the main question the study is designed to answer.
Urinary Ratio of D10PheT/D9PhOH
The ratio of D10-phenanthrene tetraol to D9-phenanthrene phenols in the urine will determine how the lung breaks down a class of cancer-causing chemicals called Polycyclic Aromatic Hydrocarbons (PAHs). The higher this ratio the more the lungs break down these chemicals through harmful pathways, which might increase cancer risk. The lower the ratio the more the lung breaks down the chemicals through safer pathways.
Measured: 24 hours after vaping phenanthrene
TNE
Total nicotine equivalents will be measured in the urine samples to confirm that study participants are not using tobacco or nicotine products.
Measured: Baseline measure
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Aug 2025
- Study start1 Sep 2026
- Primary completion1 Sep 2027 (estimated)
- Study completion30 Jun 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Former SmokerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- All study participants (Former Daily Smokers and Non-smokers) will be asked to vape D10-phenanthrene to see how their lungs breakdown a class of cancer-causing chemicals known as polycyclic aromatic hydrocarbons \[PAHs\].
- Masking
- None (open label)
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Minnesota
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Stephen Hecht, Principal investigator, University of Minnesota
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07134426
- Sponsor's protocol ID
- 2022LS127
- Status last verified
- Sep 2026
- First submitted
- 14 Aug 2025
- Last updated
- 3 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Investigating Vaped Phenanthrene Biomarkers in Former Smokers
- ClinicalTrials.gov ID
- NCT07134426
- Acronym / sponsor ID
- 2022LS127
- Conditions
- Former Smoker, Non-Smoker
- Keywords
- Smoking, Tobacco, Vaping, Former Smoker, Non-Smoker
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- University of MinnesotaUniversity, hospital or other
- Study start
- 1 Sep 2026 (actual)
- Primary completion
- 1 Sep 2027 (estimated)
- Study completion
- 30 Jun 2028 (estimated)
- First posted
- 21 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Some people who used to smoke cigarettes continue to be at higher risk of developing lung cancer, even years after quitting. This study will look to see if a specific chemical, phenanthrene, is broken down in the lungs of former smokers through more harmful pathways than never-smokers. If former smokers break down chemicals that enter their lungs through more harmful pathways this might be putting them at higher risk for developing lung cancer even though they quit smoking. This information may help find better ways to prevent or treat cancer in the future.
This study is under an IND, but the drug is not being studied; instead, it is being used as a marker for drug metabolism.
Study design
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- All study participants (Former Daily Smokers and Non-smokers) will be asked to vape D10-phenanthrene to see how their lungs breakdown a class of cancer-causing chemicals known as polycyclic aromatic hydrocarbons [PAHs].
| Arm | Type | Receives |
|---|---|---|
| D10-phenanthrene | Other | Other: D10-phenanthreneAll study participants (Former Daily Smokers and Non-smokers) will be asked to vape D10-phenanthrene to see how their lungs breakdown a class of cancer-causing chemicals known as polycyclic aromatic hydrocarbons [PAHs]. |
Who may qualify
- Ages
- 21 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- > 21 years of age
- In good physical \& mental health
- In stable physical \& mental health
- Have tried vaping
- Former daily cigarette smokers who quit 1-20 year ago
Key exclusion criteria (6 listed)
- Has any respiratory disease (ex - asthma, COPD, etc...)
- Has/had high blood pressure
- Has/had liver disease
- Has/had cancer
- Has experience negative effects when vaped previously
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| D10-phenanthreneAll study participants (Former Daily Smokers and Non-smokers) will be asked to vape D10-phenanthrene to see how their lungs breakdown a class of cancer-causing chemicals known as polycyclic aromatic hydrocarbons [PAHs]. | Other | D10-phenanthrene |
Primary outcome
Urinary Ratio of D10PheT/D9PhOH
Time frame: 24 hours after vaping phenanthrene
The ratio of D10-phenanthrene tetraol to D9-phenanthrene phenols in the urine will determine how the lung breaks down a class of cancer-causing chemicals called Polycyclic Aromatic Hydrocarbons (PAHs). The higher this ratio the more the lungs break down these chemicals through harmful pathways, which might increase cancer risk. The lower the ratio the more the lung breaks down the chemicals through safer pathways.
TNE
Time frame: Baseline measure
Total nicotine equivalents will be measured in the urine samples to confirm that study participants are not using tobacco or nicotine products.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Former Smoker
Active, not recruitingPhase 1
A Study of Exercise and Pharmacologic Intervention on Systemic Inflammation
Smokers, Former Smokers
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Stephen Hecht principal investigator
University of Minnesota
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing D10-phenanthrene in people with Former Smoker and Non-Smoker, run by University of Minnesota at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 3 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Aleksandra Alcheva (612-422-8902, alche003@umn.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Urinary Ratio of D10PheT/D9PhOH (time frame: 24 hours after vaping phenanthrene). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Sep 2026; AzTrials last refreshed its copy on 27 Oct 2026.